Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy

CD40 expression correlates with the type I anti-tumor response and better survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RAS(mut) melanoma compared to nevi. RAS mutation correlates with reduced CD40 expression in malignant melanoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Chi, Richmond, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582157/
https://www.ncbi.nlm.nih.gov/pubmed/34758832
http://dx.doi.org/10.1186/s12943-021-01442-3
_version_ 1784596925222223872
author Yan, Chi
Richmond, Ann
author_facet Yan, Chi
Richmond, Ann
author_sort Yan, Chi
collection PubMed
description CD40 expression correlates with the type I anti-tumor response and better survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RAS(mut) melanoma compared to nevi. RAS mutation correlates with reduced CD40 expression in malignant melanoma. CD40 expression is associated with better response to immune checkpoint blockade therapy in melanoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-021-01442-3.
format Online
Article
Text
id pubmed-8582157
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85821572021-11-15 Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy Yan, Chi Richmond, Ann Mol Cancer Letter to the Editor CD40 expression correlates with the type I anti-tumor response and better survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RAS(mut) melanoma compared to nevi. RAS mutation correlates with reduced CD40 expression in malignant melanoma. CD40 expression is associated with better response to immune checkpoint blockade therapy in melanoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-021-01442-3. BioMed Central 2021-11-10 /pmc/articles/PMC8582157/ /pubmed/34758832 http://dx.doi.org/10.1186/s12943-021-01442-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Yan, Chi
Richmond, Ann
Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
title Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
title_full Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
title_fullStr Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
title_full_unstemmed Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
title_short Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
title_sort hiding in the dark: pan-cancer characterization of expression and clinical relevance of cd40 to immune checkpoint blockade therapy
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582157/
https://www.ncbi.nlm.nih.gov/pubmed/34758832
http://dx.doi.org/10.1186/s12943-021-01442-3
work_keys_str_mv AT yanchi hidinginthedarkpancancercharacterizationofexpressionandclinicalrelevanceofcd40toimmunecheckpointblockadetherapy
AT richmondann hidinginthedarkpancancercharacterizationofexpressionandclinicalrelevanceofcd40toimmunecheckpointblockadetherapy

Ejemplares similares